Standalone Unaudited financial results for the quarter and half year ended on 30th September, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jenburkt Pharmaceuticals reported revenue from operations of Rs 4,555.76 lacs in Q2 FY26, up about 10.5% from Rs 4,121.59 lacs in Q2 FY25. For the half year, revenue grew to Rs 8,108.44 lacs versus Rs 7,375.16 lacs in H1 FY25, a rise of roughly 10%. Profit after tax for Q2 stood at Rs 1,016.34 lacs (vs Rs 960.05 lacs) and H1 PAT at Rs 1,795.52 lacs (vs Rs 1,701.65 lacs), translating to an EPS of Rs 23.03 for the quarter and Rs 40.68 for the half year. The balance sheet remains debt-free with zero borrowings, reserves of about Rs 17,847 lacs, and Capital Work in Progress of Rs 5,221 lacs indicating ongoing capacity expansion. Operating cash flow was healthy at Rs 1,710.71 lacs for H1. The auditor's limited review report is clean with no qualifications or emphasis of matter.
Steady mid-single-digit to low-double-digit growth in revenue and profit, a debt-free balance sheet, and ongoing capex suggest stable operations with modest upside; the stock may see limited immediate reaction given the results are in line with trends rather than an outlier beat.